A clinical trial to study the effect of two drugs, Rasnadidashmool kwatha and Erandadi kwath in patients of Amavata (Rheumatoid Arthritis).

Phase 3

Not yet recruiting

Conditions: Patients of Amavata without any other co-existing disease

Registration Number: CTRI/2018/01/011537

Lead Sponsor: Ch Brahm Prakash Ayurved Charak Sansthan

Brief Summary: Amavata (rheumatoid arthritis) is one of the dreaded disease that mankind facing day by day. It not only affects the social and economic position of individual and his family but also leads to draining of national resource due to the work hours lost, resulting in diminished production. Amavata (RA) is reported to be 1-2% of general population with male and female ratio 3:1.

Rasanadidahmool kwath mentioned in Chakradutta in Amavata rogadhikara which have the properties of Amahar, Shothahar, and Shoolhar. and Erandadi kwath as comprative arm mentioned in Bhashajya Ratnavali has also shows the same property. The primary aim of this research is to find out potency of both drug in Amavata (RA) and which one is better.

**Asssesment criteria- 1-** Objective parameters like CRP, RA-factor, ESR and other will be assessed before and after treatment.

**2-**Subjective improvement will be assessed by adopting suitable scoring method.

**Study type-** Randomized comparative clinical trial

**Study time-** 24 months

**Intervention time-** 35 days

**Sample size-** 100 (50 in each group)

**Group-A-** The trial drug Rasnadidashmool kwath 48gm BD

**Group-B- T**he comparative drug Erandadi kwath 48 gm BD

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 100

Inclusion Criteria

1-Amavata of any dosha Anubandha 2-Diagnosis of Amavata as per symptoms described in Madhav Nidana 3-Diagnosis of Rheumatoid arthritis as per ACR criteria.

Exclusion Criteria

1-Pregnant women and lactating mother 2-Patients of RA with know case of rheumatic fever juvenile RA, Ankylosing spondylitis 3-Patients of RA with complications like deformity 4-Any other disorder with Amavata.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Symptomatic relief in cardinal signs and symptoms of patients	35 days
Improvement in DAS-28 Score	35 days

Secondary Outcome Measures

Name	Time	Method
Subjective improvement in the patients will be assessed by adopting suitable scoring pattern.	Decrease in elevated levels of CRP,ESR,RA factor and other biochemical parameters.

Trial Locations

Locations (1): Ch Brahm Prakash Ayurved Charak Sansthan Hospital
🇮🇳
Delhi, DELHI, India
Ch Brahm Prakash Ayurved Charak Sansthan Hospital
🇮🇳Delhi, DELHI, India
Dr Anant Kumar
Principal investigator
8384086212
kumaranant530@gmail.com